

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 May 2025 (01.05.2025)



(10) International Publication Number
WO 2025/090658 A2

(51) International Patent Classification:

C07D 231/14 (2006.01) C07D 413/12 (2006.01)
C07D 231/56 (2006.01) C07D 417/12 (2006.01)
C07D 401/12 (2006.01) C07D 487/04 (2006.01)
C07D 403/12 (2006.01) A61P 35/00 (2006.01)
C07D 405/12 (2006.01)

(21) International Application Number:

PCT/US2024/052642

(22) International Filing Date:

23 October 2024 (23.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/545,413 24 October 2023 (24.10.2023) US
63/674,639 23 July 2024 (23.07.2024) US

(71) Applicant: **TERREMOTO BIOSCIENCES, INC.**
[US/US]; 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US).

(72) Inventors: **YANG, Kin S.**; 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US). **CHU, Hang**; 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US). **REISBERG, Solomon H.**; 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US). **CHOY, Wai Yan**; 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US). **BEST-**

VATER, Brian P.; 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US). **ZAJDLIK, Adam**; 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US). **SPEVAK, Wayne**; 230 E. Grand Ave., Suite, 200, South San Francisco, California 94080 (US).

(74) Agent: **PERLA, Luis** et al.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: REVERSIBLE LYSINE COVALENT MODIFIERS OF CDK2 AND USES THEREOF




FIG 1A




FIG 1B

(57) Abstract: In some aspects, the present disclosure provides compounds of Formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), or pharmaceutically acceptable salts thereof, for the modulation of CDK2. In another aspect, the present disclosure provides methods for the treatment of diseases or disorders mediated by CDK2, such as oncology indications, using compounds of Formula (I), (II), (II-A), (II-B), (II-C), (II-D), (II-E), (II-F), (III), (IV), (IV-A), (IV-B), (IV-C), or (V), or pharmaceutically acceptable salts thereof.

[Continued on next page]

WO 2025/090658 A2

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*